Pharmaron Beijing Co., Ltd., commonly referred to as Pharmaron, is a leading contract research organisation (CRO) headquartered in Beijing, China. Established in 2004, the company has rapidly expanded its operational footprint across major regions, including North America and Europe, positioning itself as a key player in the pharmaceutical and biotechnology sectors. Pharmaron offers a comprehensive suite of services, including drug discovery, development, and manufacturing, with a focus on small molecules and biologics. Its unique integration of advanced technologies and scientific expertise enables clients to accelerate their drug development processes. Notably, Pharmaron has achieved significant milestones, such as successful collaborations with global pharmaceutical companies, solidifying its reputation for excellence in the industry. With a commitment to innovation and quality, Pharmaron continues to enhance its market position as a trusted partner in the life sciences arena.
How does Pharmaron Beijing's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pharmaron Beijing's score of 50 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Pharmaron Beijing reported total carbon emissions of approximately 395,142,930 kg CO2e, with emissions distributed across various scopes: 34,755,680 kg CO2e (Scope 1), 216,740,300 kg CO2e (Scope 2), and 395,142,930 kg CO2e (Scope 3). This represents a significant increase in emissions compared to 2022, where total emissions were approximately 163,905,130 kg CO2e for Scope 2 and 19,261,360 kg CO2e for Scope 1. Pharmaron has set ambitious climate commitments, aiming to achieve net-zero greenhouse gas emissions across its value chain by 2050. Near-term targets include a 54.60% reduction in absolute Scope 1 and 2 emissions by 2033 from a 2023 base year, and a 61.07% reduction in Scope 3 emissions per million CNY value added within the same timeframe. Long-term goals include a 90% reduction in absolute Scope 1 and 2 emissions by 2050, using 2021 as the base year, and a 97% reduction in Scope 3 emissions per million CNY value added by 2050. Pharmaron's commitment to sustainability is further underscored by its near-term goal to reduce Scope 2 emissions to near zero by 2025. The company is actively working towards these targets, which are aligned with the Science Based Targets initiative (SBTi) and reflect a commitment to limiting global warming to 1.5°C.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|
Scope 1 | 48,007,050 | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 267,941,280 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmaron Beijing is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.